Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
Apply
SNDX-5613 & Gilteritinib
SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step